ALL-SCT BFM International- HSCT in Children and Adolescents With ALL

Launched by ST. ANNA KINDERKREBSFORSCHUNG · Aug 25, 2011

Keywords

ClinConnect Summary

Patients with high risk or relapsed acute lymphoblastic leukaemia (ALL) have a worse prognosis compared to all other patients with ALL. For these patients additional therapy approaches are required after they have achieved remission with multimodal chemotherapy. Allogeneic haematopoetic stem cell transplantation shows promising results mainly due to an immunological antileukaemic control by the graft-versus-leukaemia effect but treatment related mortality and morbidity remains a serious problem.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age at time of initial diagnosis or relapse diagnosis, respectively under or equal 18 years
• • indication for allogeneic hematopoietic stem cell transplantation(HSCT)
• • complete remission before hematopoietic stem cell transplantation (HSCT)
• • written consent of the parents (legal guardian) and, if necessary, the minor patient via Informed Consent Form
• • no pregnancy
• • no secondary malignancy
• • no previous hematopoietic stem cell transplantation (HSCT)
• • hematopoietic stem cell transplantation (HSCT) is performed in a study participating centre.
• Exclusion Criteria:
• • age at time of initial diagnosis or relapse diagnosis, respectively above 18 years
• • no indication for allogeneic HSCT
• • no complete remission before SCT
• • no written consent of the parents (legal guardian) and, if necessary, the minor patient via Informed Consent Form
• • pregnancy
• • secondary malignancy
• • previous HSCT
• • HSCT is not performed in a study participating centre.